Silencing CDC25A inhibits the proliferation of liver cancer cells by downregulating IL‑6 in vitro and in vivo

Chen,Si; Tang,Yanping; Yang,Chun; Li,Kezhi; Huang,Xiaoqing; Cao,Ji

doi:10.3892/ijmm.2020.4461

Silencing CDC25A inhibits the proliferation of liver cancer cells by downregulating IL‑6 in vitro and in vivo

Authors:
- Si Chen
- Yanping Tang
- Chun Yang
- Kezhi Li
- Xiaoqing Huang
- Ji Cao
View Affiliations

Affiliations: Department of Research, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: January 9, 2020 https://doi.org/10.3892/ijmm.2020.4461
Pages: 743-752
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cell division cycle 25A (CDC25A) is a core regulator of the cell cycle that has a dual‑specific phosphatase activity, which is closely associated with the occurrence and development of a tumor, and is overexpressed in liver cancer. However, the molecular mechanism of CDC25A in the development of liver cancer remains unclear. The purpose of the present study was to further investigate the effect of CDC25A on cell proliferation in vitro and in vivo and to investigate whether an interaction exists between CDC25A and interleukin (IL)‑6 in liver cancer. An Affymetrix human gene expression profiling chip screened differentially expressed genes in HepG2 cells with silenced CDC25A and the IL‑6 signaling pathway was revealed to be significantly inhibited (P<0.05). In the present study, the effects of CDC25A on cell proliferation and migration were analyzed using cell cycle, MTT and Transwell assays. Reverse transcription‑quantitative PCR, western blot and immunohistochemistry analyses confirmed that silencing the CDC25A gene downregulated the expression of IL‑6 in HepG2 cells and the mRNA and protein expression of IL‑1β, mitogen‑activated protein kinase kinase kinase 14 (NIK) and nuclear factor‑κB (NF‑κB), which are regulatory molecules upstream of IL‑6. In addition, silencing CDC25A by short hairpin RNA inhibited the development of liver cancer xenograft tumor types in nude mice, and decreased the expression of IL‑1β, NIK, NF‑κB and IL‑6 in xenograft tumor types. In conclusion, silencing CDC25A significantly inhibited the proliferation of liver cancer cells in vitro and in vivo, potentially via an interaction with IL‑6 through the downregulation of the IL‑1β/NIK/NF‑κB signaling axis.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Yamashita T and Kaneko S: Liver cancer. Rinsho byori. 64:787–796. 2016.In Japanese. PubMed/NCBI
4	Lu X, Sun W, Tang Y, Zhu L, Li Y, Ou C, Yang C, Su J, Luo C, Hu Y and Cao J: Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta-analysis and cross-species comparison. Mol Med Rep. 13:1172–1178. 2016. View Article : Google Scholar :
5	Shen T and Huang S: The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 12:631–639. 2012. View Article : Google Scholar : PubMed/NCBI
6	Harbour JW, Luo RX, Dei Santi A, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 98:859–869. 1999. View Article : Google Scholar : PubMed/NCBI
7	Sur S and Agrawal DK: Phosphatases and kinases regulating CDC25 activity in the cell cycle: Clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem. 416:1–14. 2016. View Article : Google Scholar
8	Li H, Jiang M, Cui M, Feng G, Dong J, Li Y, Xiao H and Fan S: MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A. Biochem Biophys Res Commun. 512:392–398. 2019. View Article : Google Scholar : PubMed/NCBI
9	Qin H and Liu W: MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A. J Cell Physiol. 234:3526–3537. 2019. View Article : Google Scholar
10	Luo A, Zhou X, Shi X, Zhao Y, Men Y, Chang X, Chen H, Ding F, Li Y, Su D, et al: Exosome-derived miR-339-5p mediates radio-sensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. Oncogene. 38:4990–5006. 2019. View Article : Google Scholar : PubMed/NCBI
11	Ataie-Kachoie P, Pourgholami MH, Richardson DR and Morris DL: Gene of the month: Interleukin 6 (IL-6). J Clin Pathol. 67:932–937. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sato Y, Goto Y, Narita N and Hoon DS: Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2(Suppl 1): S205–S214. 2009. View Article : Google Scholar
13	Yuan FJ, Zhou YS, Wei Y, Zou C, Chen L, Huang L and Liu Z: Increased expression of IL-6 mRNA in hepatocellular carcinoma cell lines correlates with biological characteristics. Asian Pac J Cancer Prev. 12:3361–3365. 2011.PubMed/NCBI
14	Schmidt-Arras D and Rose-John S: IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhou M, Yang H, Learned RM, Tian H and Ling L: Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun. 8:154332017. View Article : Google Scholar : PubMed/NCBI
16	Rayet B and Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 18:6938–6947. 1999. View Article : Google Scholar : PubMed/NCBI
17	Yin L and Yu X: Arsenic-induced apoptosis in the p53-proficient and p53-deficient cells through differential modulation of NFkB pathway. Food Chem Toxicol. 118:849–860. 2018. View Article : Google Scholar : PubMed/NCBI
18	Sheng ML, Xu GL, Zhang CH, Jia WD, Ren WH, Liu WB, Zhou T, Wang YC, Lu ZL, Liu WF, et al: Aberrant estrogen receptor alpha expression correlates with hepatocellular carcinoma metastasis and its mechanisms. Hepatogastroenterology. 61:146–150. 2014.PubMed/NCBI
19	Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, Zhang W, Han X, Tan R and Shen P: Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol. 228:216–229. 2012. View Article : Google Scholar : PubMed/NCBI
20	Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013. View Article : Google Scholar
21	Hong HY, Choi J, Cho YW and Kim BC: Cdc25A promotes cell survival by stimulating NF-κB activity through IκB-α phosphorylation and destabilization. Biochem Biophys Res Commun. 420:293–296. 2012. View Article : Google Scholar : PubMed/NCBI
22	He P: Screening of differentially expressed genes in liver cancer HepG2 cells after silencing CDC25A gene. Guangxi Med Univ. 2018.
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Källström H, Lindqvist A, Pospisil V, Lundgren A and Rosenthal CK: Cdc25A localisation and shuttling: Characterisation of sequences mediating nuclear export and import. Exp Cell Res. 303:89–100. 2005. View Article : Google Scholar
25	Dozier C, Mazzolini L, Cénac C, Froment C, Burlet-Schiltz O, Besson A and Manenti S: CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability. Oncogene. 36:3781–3788. 2017. View Article : Google Scholar : PubMed/NCBI
26	Wang Z, Kar S and Carr BI: Cdc25A protein phosphatase: A therapeutic target for liver cancer therapies. Anticancer Agents Med Chem. 8:863–871. 2008. View Article : Google Scholar : PubMed/NCBI
27	Zou X, Tsutsui T, Ray D, Blomquist JF, Ichijo H, Ucker DS and Kiyokawa H: The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol Cell Biol. 21:4818–4828. 2001. View Article : Google Scholar : PubMed/NCBI
28	Liang J, Cao R, Zhang Y, Xia Y, Zheng Y, Li X, Wang L, Yang W and Lu Z: PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nat Commun. 7:124312016. View Article : Google Scholar : PubMed/NCBI
29	Feng X, Wu Z, Wu Y, Hankey W, Prior TW, Li L, Ganju RK, Shen R and Zou X: Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells. Mol Cell Biol. 31:3457–3471. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wang XQ, Zhu YQ, Lui KS, Cai Q, Lu P and Poon RT: Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma. Clin Cancer Res. 14:6813–6820. 2008. View Article : Google Scholar : PubMed/NCBI
31	Xu X, Yamamoto H, Sakon M, Yasui M, Ngan CY, Fukunaga H, Morita T, Ogawa M, Nagano H, Nakamori S, et al: Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res. 9:1764–1772. 2003.PubMed/NCBI
32	Xu X, Yamamoto H, Liu G, Ito Y, Ngan CY, Kondo M, Nagano H, Dono K, Sekimoto M and Monden M: CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells. Int J Mol Med. 21:145–152. 2008.PubMed/NCBI
33	Fu S and Lin J: Blocking interleukin-6 and interleukin-8 signaling inhibits cell viability, colony-forming activity, and cell migration in human triple-negative breast cancer and pancreatic cancer cells. Anticancer Res. 38:6271–6279. 2018. View Article : Google Scholar : PubMed/NCBI
34	Huang Q, Zhang Z, Liao Y, Liu C, Fan S, Wei X, Ai B and Xiong J: 17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression. J Exp Clin Cancer Res. 37:1332018. View Article : Google Scholar
35	Wang Y, Zong X, Mitra S, Mitra AK, Matei D and Nephew KP: IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI Insight. 3:pii: 122360. 2018. View Article : Google Scholar
36	Yin Z, Ma T, Lin Y, Lu X, Zhang C, Chen S and Jian Z: IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem. 119:9419–9432. 2018. View Article : Google Scholar : PubMed/NCBI
37	Bournazou E and Bromberg J: Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT. 2:e238282013.PubMed/NCBI
38	Rokavec M, Wu W and Luo JL: IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell. 45:777–789. 2012. View Article : Google Scholar : PubMed/NCBI
39	Al Zaid Siddiquee K and Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 18:254–267. 2008. View Article : Google Scholar : PubMed/NCBI
40	Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, et al: Emodin inhibits growth and induces apoptosis in an orthotopic hepato-cellular carcinoma model by blocking activation of STAT3. Br J Pharmacol. 170:807–821. 2013. View Article : Google Scholar : PubMed/NCBI
41	Ma H, Yan D, Wang Y, Shi W, Liu T, Zhao C, Huo S, Duan J, Tao J, Zhai M, et al: Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma. Cancer Sci. 110:950–961. 2019. View Article : Google Scholar : PubMed/NCBI
42	Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, Kroll Y, Boldin M, Taganov K, Groner B, et al: STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal. 7:ra112014. View Article : Google Scholar
43	Duan XH, Li H, Han XW, Ren JZ, Li FY, Ju SG, Chen PF and Kuang DL: Upregulation of IL-6 is involved in moderate hyperthermia induced proliferation and invasion of hepatocellular carcinoma cells. Eur J Pharmacol. 833:230–236. 2018. View Article : Google Scholar : PubMed/NCBI
44	Korkaya H, Liu S and Wicha MS: Regulation of cancer stem cells by cytokine networks: Attacking cancer's inflammatory roots. Clin Cancer Res. 17:6125–6129. 2011. View Article : Google Scholar : PubMed/NCBI
45	Stylianou E and Saklatvala J: Interleukin-1. Int J Biochem Cell Biol. 30:1075–1079. 1998. View Article : Google Scholar : PubMed/NCBI
46	Wu R, Chen B, Jia X, Qiu Y, Liu M, Huang C, Feng J and Wu Q: Interleukin-1β influences functional regeneration following nerve injury in mice through nuclear factor-κB signaling pathway. Immunology. 156:235–248. 2019. View Article : Google Scholar
47	Sun K, Xu L, Jing Y, Jing Y, Han Z, Chen X, Cai C, Zhao P, Zhao X and Yang L: Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-κB-IL1α/β-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis. Cancer Lett. 388:198–207. 2017. View Article : Google Scholar
48	Nomura A, Gupta VK, Dauer P, Sharma NS, Dudeja V, Merchant N, Saluja AK and Banerjee S: NFκB-mediated inva-siveness in CD133+ pancreatic TICs is regulated by autocrine and paracrine activation of IL1 signaling. Mol Cancer Res. 16:162–172. 2018. View Article : Google Scholar
49	Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA and Apte RN: IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 100:2645–2650. 2003. View Article : Google Scholar : PubMed/NCBI